Furthermore, B‐lymphocyte antigen CD19, which is expressed by B cells prior to terminal differentiation into plasma cells, is associated with the enhancement of myeloma's tumor‐propagating and drug‐resistance properties. This evidence concerns the gene CD19 and neoplasm.